Gainers
Applied Genetic Technologies (NASDAQ: AGTC) shares are trading higher after the company announced that it plans to release 12-month data for adult patients and low-dose pediatric patients in its Phase 1/2 clinical achromatopsia trials on Thursday, June 24.
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs.
Once again, some insiders took advantage of recent public share offerings to add or bolster stakes.
Again, biotechnology companies are well represented on this list.